NCT07436767
Safety and Efficacy of KL003 Cell Injection in Severe Sickle Cell Disease
StatusSuspended
PhaseNot applicable
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Stopped Trial status changed: Not Yet Recruiting → Suspended Sponsor's reason: Difficulty identifying eligible patients. Show 4 more changesShow less
- Primary completion pushed from Sep 30, 2028 to Sep 30, 2030
- Start date: Mar 1, 2026 to Mar 1, 2028
- Eligibility criteria expanded, about 37 words
- Study completion pushed from Dec 31, 2028 to Dec 31, 2030
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
Endpoints
Primary
The proportion of subjects who achieve successful engraftment of CD34⁺ cells modified with the βA-T87Q-globin lentiviral vector
Timeframe: From Day 0 to Day 42 after cell infusion
Incidence and severity of adverse events
Timeframe: Adverse events will be monitored from baseline through study completion, up to 24 months.
Arms and interventions
ExperimentalExperimental
A single intravenous infusion of ≥ 3.0 × 10\^6 CD34+ cells/kg was administered.
Genetic: KL003 Cell Injection
Sites
1 site in 1 country
- Regenerative Medicine CenterTianjin, Tianjin Municipality, China